Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Int.biotech. (IBT) Share Price

Price 986.00p on 09-01-2026 at 19:40:07
Change 18.00p 1.86%
Buy 984.00p
Sell 980.00p
Last Trade: Buy 1,472.00 at 986.00p
Day's Volume: 137,977
Last Close: 986.00p
Open: 976.00p
ISIN: GB0004559349
Day's Range 968.00p - 986.00p
52wk Range: 480.00p - 1,000.00p
Market Capitalisation: £314.56m
VWAP: 977.55988p
Shares in Issue: 31.90m

Int.biotech. (IBT) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 1,472 986.00p Suspected BUY Trade
16:35:03 - 09-Jan-26
Buy* 70 982.4188p Ordinary
16:25:34 - 09-Jan-26
Buy* 370 982.4227p Ordinary
16:24:14 - 09-Jan-26
Buy* 132 982.406p Suspected BUY Trade
16:20:12 - 09-Jan-26
Unknown* 10,000 980.00p Negotiated Trade
16:19:53 - 09-Jan-26
Buy* 1,400 982.4434p Ordinary
16:15:29 - 09-Jan-26
Buy* 386 982.4617p Ordinary
16:13:58 - 09-Jan-26
Buy* 19 982.48p Ordinary
16:12:50 - 09-Jan-26
Unknown* 2,940 982.00p Ordinary
15:59:27 - 09-Jan-26
Sell* 10 980.00p Automatic Execution
15:59:03 - 09-Jan-26
See more Int.biotech. trades

Int.biotech. (IBT) Share Price History

Time period:
to
Date Open High Low Close Volume
9th Jan 2026 (Fri) 976.00 986.00 968.00 986.00 137,977
8th Jan 2026 (Thu) 974.00 980.00 968.00 968.00 90,166
7th Jan 2026 (Wed) 948.00 972.00 944.00 970.00 111,724
6th Jan 2026 (Tue) 938.00 948.00 930.00 946.00 55,447
5th Jan 2026 (Mon) 984.00 984.00 934.00 934.00 123,356
2nd Jan 2026 (Fri) 980.00 982.00 960.00 966.00 65,561
1st Jan 2026 (Thu) 964.00 964.00 964.00 964.00 0
31st Dec 2025 (Wed) 976.00 982.00 964.00 964.00 28,756
30th Dec 2025 (Tue) 976.00 982.00 960.00 960.00 38,384
29th Dec 2025 (Mon) 974.00 984.00 966.00 972.00 49,148
26th Dec 2025 (Fri) 980.00 980.00 980.00 980.00 0
25th Dec 2025 (Thu) 980.00 980.00 980.00 980.00 0
24th Dec 2025 (Wed) 990.00 990.00 978.00 980.00 42,795
23rd Dec 2025 (Tue) 984.00 990.00 980.00 980.00 43,671
22nd Dec 2025 (Mon) 970.00 990.00 966.00 990.00 43,138
19th Dec 2025 (Fri) 956.00 984.00 952.00 972.00 306,348
18th Dec 2025 (Thu) 976.00 976.00 950.00 960.00 109,184
17th Dec 2025 (Wed) 986.00 990.00 976.00 982.00 110,328
16th Dec 2025 (Tue) 1,000.00 1,000.00 980.00 996.00 125,032
15th Dec 2025 (Mon) 996.00 1,000.00 992.00 1,000.00 159,077
12th Dec 2025 (Fri) 974.00 990.00 974.00 990.00 101,230
11th Dec 2025 (Thu) 970.00 974.00 960.00 974.00 43,673
10th Dec 2025 (Wed) 972.00 972.00 960.00 970.00 49,097
See more Int.biotech. price history

Int.biotech. (IBT) Regulatory News

Date Source Headline
9th Jan 2026 11:57 am RNS Net Asset Value(s)
8th Jan 2026 11:59 am RNS Net Asset Value(s)
7th Jan 2026 11:37 am RNS Net Asset Value(s)
6th Jan 2026 11:24 am RNS Net Asset Value(s)
5th Jan 2026 4:52 pm RNS Block listing Interim Review
5th Jan 2026 11:50 am RNS Net Asset Value(s)
2nd Jan 2026 12:02 pm RNS Net Asset Value(s)
31st Dec 2025 11:47 am RNS Net Asset Value(s)
30th Dec 2025 11:55 am RNS Net Asset Value(s)
29th Dec 2025 11:45 am RNS Net Asset Value(s)
See more Int.biotech. regulatory news

Int.biotech. (IBT) Share News

UK dividends calendar - next 7 days

22nd Dec 2025 14:43

Read More

International Biotechnology beats benchmark with 0.7% NAV gain

6th Nov 2025 19:17

(Alliance News) - International Biotechnology Trust PLC on Thursday said its portfolio continued to outperform the sector benchmark as the company reported full-year results. Read More

IN BRIEF: International Biotechnology Trust notes Novo to buy Akero

9th Oct 2025 15:40

International Biotechnology Trust PLC - investor in biotech and life science companies - Notes portfolio firm Akero Therapeutics Inc as agreed to be taken over by Novo Nordisk AS in a deal worth up to EUR5.2 billion. Novo Nordisk will pay an initial USD54 per share, with a contingent portion of the deal worth USD6 per share. The Bagsvaerd, Denmark-based pharmaceuticals company will pay an initial EUR4.7 billion to buy the firm, and a potential additional payment of EUR500 million, hinging on US regulatory approval for key Akero treatment Efruxifermin. The deal adds Akero's Efruxifermin to Novo Nordisk's portfolio. The asset is aimed at treating metabolic dysfunction-associated steatohepatitis, a disease caused by fat buildup in the liver. Read More

International Biotechnology to raise unquoted exposure with Schroders

2nd Oct 2025 13:31

(Alliance News) - International Biotechnology Trust PLC on Thursday said it has partnered with Schroders Capital to access more investees in the earlier stages of development. Read More

UK dividends calendar - next 7 days

15th Aug 2025 16:46

Read More

See more Int.biotech. news
FTSE 100 Latest
Value10,124.60
Change79.91

Login to your account

Forgot Password?

Not Registered